JP2023537002A5 - - Google Patents

Info

Publication number
JP2023537002A5
JP2023537002A5 JP2023507973A JP2023507973A JP2023537002A5 JP 2023537002 A5 JP2023537002 A5 JP 2023537002A5 JP 2023507973 A JP2023507973 A JP 2023507973A JP 2023507973 A JP2023507973 A JP 2023507973A JP 2023537002 A5 JP2023537002 A5 JP 2023537002A5
Authority
JP
Japan
Application number
JP2023507973A
Other languages
Japanese (ja)
Other versions
JP2023537002A (ja
JP7792395B2 (ja
JPWO2022032004A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/044801 external-priority patent/WO2022032004A2/en
Publication of JP2023537002A publication Critical patent/JP2023537002A/ja
Publication of JP2023537002A5 publication Critical patent/JP2023537002A5/ja
Publication of JPWO2022032004A5 publication Critical patent/JPWO2022032004A5/ja
Priority to JP2025250936A priority Critical patent/JP2026034608A/ja
Application granted granted Critical
Publication of JP7792395B2 publication Critical patent/JP7792395B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023507973A 2020-08-06 2021-08-05 抗クローディン18.2多重特異性抗体及びそれらの使用 Active JP7792395B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025250936A JP2026034608A (ja) 2020-08-06 2025-12-15 抗クローディン18.2多重特異性抗体及びそれらの使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063061895P 2020-08-06 2020-08-06
US63/061,895 2020-08-06
US202063074582P 2020-09-04 2020-09-04
US63/074,582 2020-09-04
US202163144657P 2021-02-02 2021-02-02
US63/144,657 2021-02-02
PCT/US2021/044801 WO2022032004A2 (en) 2020-08-06 2021-08-05 Anti-claudin 18.2 multi-specific antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025250936A Division JP2026034608A (ja) 2020-08-06 2025-12-15 抗クローディン18.2多重特異性抗体及びそれらの使用

Publications (4)

Publication Number Publication Date
JP2023537002A JP2023537002A (ja) 2023-08-30
JP2023537002A5 true JP2023537002A5 (https=) 2024-08-13
JPWO2022032004A5 JPWO2022032004A5 (https=) 2024-08-13
JP7792395B2 JP7792395B2 (ja) 2025-12-25

Family

ID=80117669

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023507973A Active JP7792395B2 (ja) 2020-08-06 2021-08-05 抗クローディン18.2多重特異性抗体及びそれらの使用
JP2025250936A Pending JP2026034608A (ja) 2020-08-06 2025-12-15 抗クローディン18.2多重特異性抗体及びそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025250936A Pending JP2026034608A (ja) 2020-08-06 2025-12-15 抗クローディン18.2多重特異性抗体及びそれらの使用

Country Status (5)

Country Link
US (1) US20230279152A1 (https=)
EP (1) EP4192879A4 (https=)
JP (2) JP7792395B2 (https=)
KR (1) KR20230070203A (https=)
WO (2) WO2022032003A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12459980B2 (en) 2018-07-25 2025-11-04 AskGene Pharma, Inc. IL-21 prodrugs and methods of use thereof
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
WO2021142471A1 (en) 2020-01-11 2021-07-15 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
JP2025511493A (ja) 2022-05-31 2025-04-16 エルジー エナジー ソリューション リミテッド リチウム二次電池用複合固体電解質及びこの製造方法
CN119101162A (zh) * 2023-06-07 2024-12-10 江苏奥赛康生物医药有限公司 一种抗cldn18_2的抗体及体外诊断试剂盒
CN119487068A (zh) * 2023-06-08 2025-02-18 德琪(杭州)生物有限公司 抗cldn18.2抗体及其诊断用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2436397B1 (en) * 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
SG11201702606TA (en) * 2014-10-03 2017-04-27 Massachusetts Inst Technology Antibodies that bind ebola glycoprotein and uses thereof
WO2016196343A1 (en) * 2015-05-29 2016-12-08 Genentech, Inc. Humanized anti-ebola virus glycoprotein antibodies and methods of use
JP6768011B2 (ja) * 2015-06-23 2020-10-14 バイエル ファーマ アクチエンゲゼルシャフト キネシンスピンドルタンパク質(ksp)阻害剤の抗cd123抗体との抗体薬物複合体
SG11202007074PA (en) * 2018-05-18 2020-08-28 Lanova Medicines Ltd Company Anti-claudin 18.2 antibodies and uses thereof
CN111867630B (zh) * 2018-06-17 2023-10-13 上海健信生物医药科技有限公司 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
CN112770723B (zh) * 2018-07-25 2024-08-02 阿克罗斯生物科学公司 Cldn 18.2特异性单克隆抗体及其使用方法
JOP20210022A1 (ar) * 2018-08-03 2021-01-28 Amgen Inc بنيات جسم مضاد لـ cldn18.2وcd3
US10522488B1 (en) * 2018-10-31 2019-12-31 Taiwan Semiconductor Manufacturing Company, Ltd. Patterning polymer layer to reduce stress
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途

Similar Documents

Publication Publication Date Title
BR112023012656A2 (https=)
BR112021014123A2 (https=)
JP2023537002A5 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR102021018859A2 (https=)
BR112023016292A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)
BR102021016176A2 (https=)
BR102021016200A2 (https=)
BR102021015566A2 (https=)
BR102021015450A8 (https=)
BR102021015247A2 (https=)
BR102021015220A2 (https=)
BR102021014044A2 (https=)